Characterizing Oral Cancer Progression via Saliva Proteomics
通过唾液蛋白质组学表征口腔癌的进展
基本信息
- 批准号:7872959
- 负责人:
- 金额:$ 35.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAnalytical ChemistryAreaAwardBioinformaticsBiologicalBiological MarkersBiopsyCancer DiagnosticsCancer EtiologyCancer PatientCarcinomaCationsCause of DeathChemistryClinicClinicalCollaborationsComplementComplexContractsCoupledDataData AnalysesData SetDetectionDevelopmentDiagnosisDiagnosticDiagnostic Neoplasm StagingDiagnostic testsEarly DiagnosisEffectivenessEnsureEnvironmentEpithelialFractionationFundingGoalsHumanHybridsIndividualJointsLabelLiquid substanceMalignant NeoplasmsMass Spectrum AnalysisMethodsModelingNamesOralPaperPatient MonitoringPatientsPeptidesPhasePositioning AttributePostdoctoral FellowPremalignantProbabilityProcessProteinsProteomeProteomicsPublic HealthPublishingReagentResearchResearch PersonnelRisk FactorsSalivaSalivarySamplingScreening for Oral CancerScreening procedureSmokingStagingSurvival RateTechnologyTestingTimeTissue SampleTissuesTrainingTranslational ResearchTranslationsUnited StatesUpdateValidationWorkbasecancer chemopreventioncancer sitecandidate validationclinical Diagnosisclinical practicegraduate studentimprovedmalignant mouth neoplasmmolecular markermouth squamous cell carcinomanoveloral lesionoutcome forecastprogramssaliva proteomesuccesstandem mass spectrometrytooltumortumor progression
项目摘要
DESCRIPTION (provided by applicant): Oral cancer accounts for over 30,000 cases of cancer per year in the United States and is the sixth most common cancer worldwide. The five-year survival rate (approximately 50%) from these carcinomas is one of the worst for the major sites of cancer development, and has not significantly improved in the past 30 years. Reliable molecular markers that can predict this transition early in the process and be screened for in readily obtained clinical samples would enable more informed treatment and monitoring of patients, and help to significantly improve the prognosis of oral cancer patients. The overall objective of the proposed work is to address this critical need by identifying protein biomarkers in whole human saliva that are predictive of oral cancer development. This objective will be achieved through three Specific Aims: 1) Characterize changes in the secreted saliva proteome associated with oral cancer progression; 2) Characterize changes in the exfoliated oral epithelial cellular proteome and tissue biopsies associated with oral cancer progression; 3) Validate candidate predictive oral cancer protein biomarkers via targeted mass spectrometric analysis. Strategies developed by the assembled research team, including novel peptide fractionation methods, targeted mass spectrometry-based biomarker validation methods, and enabling computational and bioinformatic tools will be employed. A highly informative oral cancer progression model will be analyzed, composed of unique clinical samples collected from individuals at intermediate stages of oral cancer development, controlling for the risk factor of smoking, and enabling the identification of diagnostic protein changes at the earliest stages of cancer development. Taken together, the combination of advanced technologies, availability of unique clinical samples, and the collective expertise of the assembled research team will provide for the successful discovery and validation of promising clinical biomarkers of oral cancer.
RELEVANCE TO PUBLIC HEALTH: The proposed studies will identify proteins in clinical saliva samples that are predictive of oral cancer development, providing promising diagnostic markers which can be developed into routine clinical patient tests. As such the findings from the proposed studies will have a direct impact on improving the diagnosis and treatment of oral cancer in the clinic, thereby leading to a decrease in the significant suffering and death caused by this cancer.
描述(由申请人提供):口腔癌在美国每年有超过30,000例癌症病例,是全球第六大常见癌症。这些癌症的五年生存率(约50%)是癌症发展的主要部位中最差的之一,并且在过去30年中没有显著改善。可靠的分子标记物可以在早期预测这种转变,并在容易获得的临床样本中进行筛选,这将使患者能够获得更明智的治疗和监测,并有助于显着改善口腔癌患者的预后。拟议工作的总体目标是通过鉴定整个人类唾液中预测口腔癌发展的蛋白质生物标志物来解决这一关键需求。这一目标将通过三个具体目标实现:1)表征与口腔癌进展相关的分泌唾液蛋白质组的变化; 2)表征与口腔癌进展相关的脱落口腔上皮细胞蛋白质组和组织活检的变化; 3)通过靶向质谱分析筛选候选预测性口腔癌蛋白质生物标志物。将采用由组装的研究团队开发的策略,包括新颖的肽分馏方法,基于质谱的靶向生物标志物验证方法以及启用计算和生物信息学工具。将分析高度信息化的口腔癌进展模型,该模型由从口腔癌发展中期个体收集的独特临床样本组成,控制吸烟的风险因素,并能够在癌症发展的最早阶段识别诊断蛋白质变化。总之,先进技术的结合,独特的临床样本的可用性,以及集合的研究团队的集体专业知识将为成功发现和验证有前途的口腔癌临床生物标志物提供条件。
与公共卫生的相关性:拟议的研究将确定临床唾液样本中预测口腔癌发展的蛋白质,提供有希望的诊断标记物,可用于常规临床患者测试。因此,拟议研究的结果将对改善临床口腔癌的诊断和治疗产生直接影响,从而减少这种癌症造成的重大痛苦和死亡。
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantitative proteomic analysis of oral brush biopsies identifies secretory leukocyte protease inhibitor as a promising, mechanism-based oral cancer biomarker.
口腔刷活检的定量蛋白质组学分析确定分泌性白细胞蛋白酶抑制剂是一种有前景的基于机制的口腔癌生物标志物
- DOI:10.1371/journal.pone.0095389
- 发表时间:2014
- 期刊:
- 影响因子:3.7
- 作者:Yang Y;Rhodus NL;Ondrey FG;Wuertz BR;Chen X;Zhu Y;Griffin TJ
- 通讯作者:Griffin TJ
LTQ-iQuant: A freely available software pipeline for automated and accurate protein quantification of isobaric tagged peptide data from LTQ instruments.
- DOI:10.1002/pmic.201000189
- 发表时间:2010-10
- 期刊:
- 影响因子:3.4
- 作者:Onsongo, Getiria;Stone, Matthew D.;Van Riper, Susan K.;Chilton, John;Wu, Baolin;Higgins, LeeAnn;Lund, Troy C.;Carlis, John V.;Griffin, Timothy J.
- 通讯作者:Griffin, Timothy J.
Improved intensity-based label-free quantification via proximity-based intensity normalization (PIN).
- DOI:10.1021/pr400866r
- 发表时间:2014-03-07
- 期刊:
- 影响因子:4.4
- 作者:Van Riper SK;de Jong EP;Higgins L;Carlis JV;Griffin TJ
- 通讯作者:Griffin TJ
A dynamic range compression and three-dimensional peptide fractionation analysis platform expands proteome coverage and the diagnostic potential of whole saliva.
- DOI:10.1021/pr900675w
- 发表时间:2009-12
- 期刊:
- 影响因子:4.4
- 作者:Bandhakavi, Sricharan;Stone, Matthew D.;Onsongo, Getiria;Van Riper, Susan K.;Griffin, Timothy J.
- 通讯作者:Griffin, Timothy J.
Protein relative abundance patterns associated with sucrose-induced dysbiosis are conserved across taxonomically diverse oral microcosm biofilm models of dental caries.
- DOI:10.1186/s40168-015-0136-z
- 发表时间:2015-12-19
- 期刊:
- 影响因子:15.5
- 作者:Rudney JD;Jagtap PD;Reilly CS;Chen R;Markowski TW;Higgins L;Johnson JE;Griffin TJ
- 通讯作者:Griffin TJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY J. GRIFFIN其他文献
TIMOTHY J. GRIFFIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY J. GRIFFIN', 18)}}的其他基金
Microbiome-derived regulators of therapy-resistant colorectal tumors
耐药性结直肠肿瘤的微生物组衍生调节因子
- 批准号:
10352947 - 财政年份:2022
- 资助金额:
$ 35.08万 - 项目类别:
Microbiome-derived regulators of therapy-resistant colorectal tumors
耐药性结直肠肿瘤的微生物组衍生调节因子
- 批准号:
10680364 - 财政年份:2022
- 资助金额:
$ 35.08万 - 项目类别:
Spingolipids in HIV-associated Chronic Obstructive Pulmonary Disease
鞘脂在 HIV 相关慢性阻塞性肺疾病中的作用
- 批准号:
9789353 - 财政年份:2018
- 资助金额:
$ 35.08万 - 项目类别:
Expanding multiplexed kinase biosensor analysis to SWATH-MS (Part 2 of 2)
将多重激酶生物传感器分析扩展到 SWATH-MS(第 2 部分,共 2 部分)
- 批准号:
9471698 - 财政年份:2016
- 资助金额:
$ 35.08万 - 项目类别:
A Galaxy‐based multi‐omic informatics hub for cancer researchers
一个基于 Galaxy 的癌症研究人员多组学信息学中心
- 批准号:
9092938 - 财政年份:2016
- 资助金额:
$ 35.08万 - 项目类别:
Characterizing Oral Cancer Progression via Saliva Proteomics
通过唾液蛋白质组学表征口腔癌的进展
- 批准号:
7475788 - 财政年份:2007
- 资助金额:
$ 35.08万 - 项目类别:
Characterizing Oral Cancer Progression via Saliva Proteomics
通过唾液蛋白质组学表征口腔癌的进展
- 批准号:
7625130 - 财政年份:2007
- 资助金额:
$ 35.08万 - 项目类别:
Characterizing Oral Cancer Progression via Saliva Proteomics
通过唾液蛋白质组学表征口腔癌的进展
- 批准号:
7322887 - 财政年份:2007
- 资助金额:
$ 35.08万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.08万 - 项目类别:
Research Grant